Results 181 to 190 of about 68,610 (290)

Orphan Drug Approval in Canada, 1999-2022: A Cross-sectional Study. [PDF]

Int J Health Policy Manag
Lexchin J.
europepmc   +1 more source

NAD+‒circadian rhythm coupling in dementia

Alzheimer's &Dementia, Volume 22, Issue 5, May 2026.
Abstract The circadian rhythm system and sleep coordinate whole‐body functions across the 24‐h cycle, yet these rhythms progressively deteriorate with neurodegenerative diseases, including dementia. Growing evidence indicates that nicotinamide adenine dinucleotide (NAD+) interacts with the circadian system through multiple molecular pathways and that ...
Shi‐qi Zhang, Jiyeon Lee, Jun‐ping Pan, Rune Enger, Harald Hrubos‐Strøm, Erik S. Musiek, Evandro Fei Fang, Weidong Le   +7 more
wiley   +1 more source

Navigating market access after conditional reimbursement: a communication roadmap for disinvesting orphan drugs. [PDF]

Int J Technol Assess Health Care
Abdallah K, Blonda A, Godman B, Huys I, Claes K, Denier Y, Simoens S.   +6 more
europepmc   +1 more source

PHP6 QUANTITATIVE ANALYSIS OF THE INFLUENCE OF DISEASE AND PRODUCT CHARACTERISTICS ON ORPHAN DRUG PRICES IN EUROPE

Value in Health, 2010
Aballea, S, Toumi, M, Vataire, AL, Millier, A, Lamure, M   +4 more
openaire   +1 more source

Translating Biomedical Research to Medical Devices: A Practical Guide and the Arteriovenous Graft Case Study

Advanced NanoBiomed Research, Volume 6, Issue 5, May 2026.
Despite significant advances, most academic research fails to result in medical products that benefit patients. This guide shares five key steps to help researchers close that gap: set clear goals, test thoroughly, protect ideas, build diverse teams, and partner with industry.
Cristina Oldani, Nina Bono, Alice Caldiroli, Stefania Adele Riboldi, Gabriele Candiani   +4 more
wiley   +1 more source

The imperative for national legislation on rare diseases in China: A policy review and call to action. [PDF]

Intractable Rare Dis Res
Li Y, Liu Z, Huang R, Liu Y.
europepmc   +1 more source

Patents, Innovation and Access to New Pharmaceuticals [PDF]

Henry Grabowski
core  

A Comparison of Regional Decisions for Doses and Administrations of New Drugs: Concordance, Discordance, and Dependencies

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1350-1361, May 2026.
Regional differences in approved drug dosages and administration are shaped by complex factors, including clinical data, prior regulatory decisions, and region‐specific considerations. This study investigated how such factors are associated with variations in approved doses across the United States Food and Drug Administration (FDA), European Medicines
Sachiko Mita, Shunsuke Ono
wiley   +1 more source

Addressing challenges along the 'access cascade' for new TB regimens. [PDF]

IJTLD Open
Servello J, de Colombani P, Dall'Olio L, Gargioni G, Raviglione MCB.   +4 more
europepmc   +1 more source

The Current Use and Future Perspectives of Biosimilars in Pediatric Healthcare: A Narrative Review

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims The integration of biosimilars into pediatric healthcare represents a significant evolution in treatment accessibility and cost‐effectiveness. Biosimilars—biological products highly similar to already approved biologics, have emerged as promising alternatives for managing chronic and rare pediatric conditions, including ...
Zubaier Ahmed, Tasfiah Tasnim Maha, Sanjana Nowsher, Wasima Taslim, Fatema‐Tuz‐Zohora, Sabrina Sharmin, Hasina Yasmin   +6 more
wiley   +1 more source